Absci Corporation Common Stock (ABSI) Stock
Key stats
- Market cap
- $1.74B
- Price / Earnings ratio
- -14.1x
- EPS (TTM)
- -$0.79
- Volume
- Loading
- 52-week high
- $12.54
- 52-week low
- $2.24
Source: third-party data provider, as of November 13, 2026
Compare with ABSI
Recent news

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
ABSI

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
ABSI

Absci Q2 Earnings Call Highlights
Absci Q2 Earnings Call Highlights
ABSI

Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
ABSI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.73
- MACD 12/26/9
- 0.17
- EMA 9 of MACD
- 0.21
- MACD histogram
- -0.03
- SMA 50
- $9.65
- Price above SMA 50
- EMA 50
- $9.71
- Price above EMA 50
- SMA 200
- $6.77
- Price above SMA 200
- EMA 200
- $6.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
ABSI

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
ABSI

Absci Q2 Earnings Call Highlights
Absci Q2 Earnings Call Highlights
ABSI

Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
ABSI

Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
ABSI

Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
ABSI

ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
ABSI

ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSI

Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today?
Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today?
ABSI

ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
ABSI
News tone: automated (AI) classification of the article's content, not a price prediction.
About Absci Corporation Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean McClain | Founder, CEO, President & Director | 1990 |
| Dr. Zachariah Jonasson Ph.D. | Chief Business Officer & CFO | 1973 |
| Mr. Todd Bedrick CPA | Senior VP & Chief Accounting Officer | — |
| Mr. Alexander Khan CPA | CVP of Finance & Head of Investor Relations | — |
| Ms. Shelby Walker J.D. | Chief Legal Officer | 1975 |
| Ms. Jeanne Schreuder M.B.A., SPHR | Senior Vice President of People & Experience | — |
| Mr. Wen Sha | Chief of Staff | — |
| Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio & Growth Strategy | — |
| Dr. Ransi Somaratne FACC, M.B.A., M.D. | Chief Medical Officer | 1966 |
| Dr. Moetaz B. Albizem M.D. | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.73
- MACD 12/26/9
- 0.17
- EMA 9 of MACD
- 0.21
- MACD histogram
- -0.03
- SMA 50
- $9.65
- Price above SMA 50
- EMA 50
- $9.71
- Price above EMA 50
- SMA 200
- $6.77
- Price above SMA 200
- EMA 200
- $6.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.00
- Average
- $15.33
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.9 | -21.8 | ||||||||||
| 2022 | -19.2 | +29.4 | -9.2 | -33.0 | -39.9 | -5.7 | -1.2 | -0.3 | -13.1 | +6.4 | -19.4 | -17.0 |
| 2023 | +38.9 | -34.4 | -12.9 | -26.7 | +52.0 | -17.4 | +43.8 | -12.3 | -29.4 | +0.8 | +35.8 | +141.4 |
| 2024 | +7.3 | +17.3 | +4.0 | -15.5 | -18.9 | -27.5 | +46.2 | +8.9 | -4.3 | +6.1 | -22.2 | -16.8 |
| 2025 | +36.9 | +4.1 | -26.6 | +27.9 | -12.5 | -5.9 | +9.3 | -17.6 | +29.9 | +36.7 | -22.9 | +14.8 |
| 2026 | -17.2 | -9.3 | +7.1 | +58.1 | +37.2 | +77.8 | -30.0 | +14.0 | +21.8 | +3.5 | +4.4 |



